antiklumpemidler: magnesiumstearat, silisiumdioksid
However, engineered bacterial therapy faces severe biosafety, ethical, and regulatory challenges, including the stability of engineered bacteria in vivo , risks of horizontal gene transfer, immunogenicity, and controllable clearance from the body
Cytokine Growth Factor Rev 25:4555
Zewen Lu 1 , Halvor Nss 2 , Matthew Gittins 1 , Amit Kishore 3 , Craig Smith 4 , Andy Vail 1 1 Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2 Department of Neurology, University of Bergen, Haukeland University Hospital, Bergen, Norway, 3 Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, 3 Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom Background and Aims: Traditional prognostic models for stroke outcomes often overlook the dynamic relationship between admission stroke severity and time to admission, limiting predictive efficiency
Bio: Dr
Available at: (Accessed January 19, 2022)
